Analytical Data
-
Gene name
CD229
- Application
-
Alternative Names
CD229；T-lymphocyte surface antigen Ly-9
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9HBG7
-
Expression Region
48-454aa
-
AA Sequence
KDSAPTVVSGILGGSVTLPLNISVDTEIENVIWIGPKNALAFA RPKENVTIMVKSYLGRLDIT KWSYSLCISN LTLNDAGSYK AQINQRNFEVTTEEEFTLFVYEQLQEPQVTMKSVKVSENFSCNITLMCSV KGAEKSVLYSWTPREPHASESNGGSILTVSRTPCDPDLPYICTAQNPVSQ RSSLPVHVGQFCTDPGASRGGTTGETVVGVLGEPVTLPLALPACRDTEKV VWLFNTSIISKEREEAATADPLIKSRDPYKNRVWVSSQDCSLKISQLKIE DAGPYHAYVCSEASSVTSMTHVTLLIYRRLRKPKITWSLRHSEDGICRIS LTCSVEDGGN TVMYTWTPLQKEAVVSQGES HLNVSWRSSE NHPNLTCTAS NPVSRSSHQFLSENICSGPERNTK
-
Molecular Weight
39 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD229, also known as SLAMF4 or A38, is a member of the signaling lymphocytic activation molecule (SLAM) family, which plays a crucial role in immune cell signaling, particularly in the regulation of T cell activation and differentiation. Research into CD229 has gained prominence due to its involvement in various immune-mediated diseases and potential implications in cancer immunotherapy. It is specifically expressed on hematopoietic cells, including T cells and B cells, where it participates in both positive and negative regulatory pathways. Understanding the structure and function of CD229 through recombinant protein studies allows researchers to dissect its signaling mechanisms and interactions with other immune checkpoint proteins. Furthermore, the generation of CD229 recombinant proteins can facilitate the development of novel therapeutic strategies, including bispecific antibodies and CAR-T cell therapies, aimed at enhancing anti-tumor responses. As interest in the modulation of immune checkpoints continues to rise in cancer treatment, CD229 serves as a promising target, warranting detailed exploration of its biological functions and potential as a therapeutic modulator in various malignancies and autoimmune disorders.
